Next Article in Journal
Development and Application of a QuEChERS-Based Liquid Chromatography Tandem Mass Spectrometry Method to Quantitate Multi-Component Alternaria Toxins in Jujube
Previous Article in Journal
Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom
Article Menu

Export Article

Open AccessArticle
Toxins 2018, 10(10), 381;

Immunogenicity of a Bivalent Non-Purified Recombinant Vaccine against Botulism in Cattle

Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul 96160-000, Brazil
Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal, Pará 68740-910, Brazil
Current address: Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie, Spielmannstr, Technische Universität Braunschweig, 7, 38106 Braunschweig, Germany.
Author to whom correspondence should be addressed.
Received: 17 August 2018 / Revised: 6 September 2018 / Accepted: 14 September 2018 / Published: 20 September 2018
(This article belongs to the Section Bacterial Toxins)
Full-Text   |   PDF [1763 KB, uploaded 8 October 2018]   |  


Botulism is a potentially fatal intoxication caused by botulinum neurotoxins (BoNTs) produced mainly by Clostridium botulinum. Vaccination against BoNT serotypes C and D is the main procedure to control cattle botulism. Current vaccines contain formaldehyde-inactivated native BoNTs, which have a time-consuming production process and pose safety risks. The development of non-toxic recombinant vaccines has helped to overcome these limitations. This study aims to evaluate the humoral immune response generated by cattle immunized with non-purified recombinant fragments of BoNTs C and D. Cattle were vaccinated in a two-dose scheme with 100, 200 and 400 µg of each antigen, with serum sampling on days 0, 56, 120, and 180 after vaccination. Animals who received either 200 or 400 μg of both antigens induced titers higher than the minimum required by the Brazilian ministry of Agriculture, Livestock and Food Supply and achieved 100% (8/8) seroconversion rate. Animals vaccinated with commercial toxoid vaccine had only a 75% (6/8) seroconversion rate for both toxins. Animals that received doses containing 400 µg of recombinant protein were the only ones to maintain titers above the required level up until day 120 post-vaccination, and to achieve 100% (8/8) seroconversion for both toxins. In conclusion, 400 µg the recombinant Escherichia coli cell lysates supernatant was demonstrated to be an affordable means of producing an effective and safe botulism vaccine for cattle. View Full-Text
Keywords: Clostridium botulinum; vaccine; botulinum neurotoxin (BoNT); cell lysate vaccine Clostridium botulinum; vaccine; botulinum neurotoxin (BoNT); cell lysate vaccine

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Moreira, C., Jr.; Ferreira, M.R.A.; da Cunha, C.E.P.; Donassolo, R.A.; Finger, P.F.; Moreira, G.M.S.G.; Otaka, D.Y.; de Sousa, L.A.; Barbosa, J.D.; Moreira, Â.N.; Salvarani, F.M.; Conceição, F.R. Immunogenicity of a Bivalent Non-Purified Recombinant Vaccine against Botulism in Cattle. Toxins 2018, 10, 381.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top